Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
Niveditha Mohan(Avera Health), M. Miles Braun(Center for Biologics Evaluation and Research), Thomas R. Cupps, Lee Jong-Hoon, Jeffrey Siegel(Center for Drug Evaluation and Research), Nancy R. Slifman(Center for Biologics Evaluation and Research), Evelyne T. Edwards(Center for Biologics Evaluation and Research)
PubMed
October 1, 2004
Cited by 198
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448